INTRODUCTION {#sec0005}
============

Parkinson's disease (PD) is the second-most occurring neurodegenerative disorder worldwide \[[@ref001]\]. The prevalence of PD increases with age and peaks at 1.5 % between 85 years and 89 years of age and 6.1-6.2 million individuals were diagnosed with PD globally in 2015-2016 \[[@ref001]\]. The main feature observed in PD patients is the aggregation of *α*-synuclein in Lewy bodies and loss of dopaminergic neurons in the substantia nigra pars compacta \[[@ref003]\]. It has been postulated that *α*-synuclein pathology spreads out from the enteric nervous system of the gastrointestinal tract to the central nervous system in the brain \[[@ref004]\]. Which is in agreement with the detection of *α*-synuclein aggregates in colonic tissue and appendix prior to the onset of PD \[[@ref005]\]. Recently, it has been shown that pathogenic *α*-synuclein aggregates spread from the gut to the brain in a mouse model, supporting Braak's hypothesis of the etiology of idiopathic PD \[[@ref007]\]. Furthermore, increasing evidence supports the involvement of the peripheral immune system in PD. Inflammation via the gastrointestinal tract, potentially through infections, may contribute to disease pathogenesis, and to the risk of PD development, which was recently reviewed in \[[@ref008]\]. Houser and Tansey proposed a model of PD pathogenesis originating from the gut where an initial inflammatory trigger could lead to a low-grade inflammation, driving shifts in the microbiota composition, and increasing gut permeability, thus allowing leakage of bacteria and their potential inflammatory metabolites \[[@ref008]\]. This leakage in gut barrier would increase the blood-brain barrier permeability and *α*-synuclein pathology, which would ultimately lead to neuroinflammation followed by neurodegeneration \[[@ref008]\]. Indeed, PD patients have an altered microbiota composition compared to healthy controls (HC) \[[@ref010]\], and one of the main bacterial metabolites, short chain fatty acids (SCFA), have been implicated in *α*-synuclein pathology and microglia activation in a mouse model of PD \[[@ref023]\]. Altered microbial composition could lead to a shift in circulating bacterial derived metabolites \[[@ref024]\], and could be involved in low-grade inflammation, an important trigger for the onset of PD \[[@ref008]\]. In this review, we aim to establish a link between the microbial composition and the reported alterations in their metabolic capacity that have profound immune modulating properties, which could potentially trigger onset, progression and etiology of PD.

ALTERED BACTERIAL-DERIVED METABOLITES IN PATIENTS WITH PARKINSON'S DISEASE {#sec0010}
==========================================================================

Although it is clear that PD patients have an altered microbiota composition \[[@ref010]\], which was reviewed recently \[[@ref025]\] and updated and merged in [Table 1](#jpd-9-jpd191780-t001){ref-type="table"}, there is a large variation among studies and there is no clear consensus about which bacteria might be involved, which might be due to several factors including sample storage, technical differences of sampling, sequencing methods, statistical approach, demographics, clinical details, and sample size \[[@ref010]\]. Nevertheless, the altered microbiota composition could result in metabolic changes in PD patients which could play an important role in disease onset and progression of PD \[[@ref024]\]. Therefore, many studies focused on metabolic biomarker screening (comparing healthy subjects with either familial PD or idiopathic PD), for an early detection of potential development of PD. The metabolic profiles of PD patients (in cerebrospinal fluid (CSF), blood or urine) usually reflect oxidative stress \[[@ref024]\] or mitochondrial dysfunction \[[@ref024]\]. However, many studies also observed differences in metabolites from bacterial origin, which are summarized in [Table 2](#jpd-9-jpd191780-t002){ref-type="table"}.

###### 

Bacterial composition alterations in PD patients compared to healthy controls

  Decreased                                                                                                                                                      Increased                                                                Method              PD    HC   Sample              Reference
  ----------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------ ----- ----- ---------------- ---------------
  *Prevotellaceae*\**, Lachnospiraceae, Puniceicoccaceae, Roseburia, Prevotella, Blautia, Clostridium XIVa*              *Bifidobacteriaceae\*, Bifidobacterium\*, Rikenellaceae, Lactobacillaceae, Lactobacillus*                       16S rRNA             64    64   Feces             \[[@ref010]\]
  *Lachnospiraceae*                                                                                                                   *Akkermansia muciniphila, Enterobacteriaceae, Lactobacillaceae*                                    16S rRNA             193   113  Feces             \[[@ref011]\]
  *Prevotella copri, Eubacterium bioforme*                                                                                                  *Akkermansia muciniphila,* unclassified Firmicutes                                     Shotgun metagenomics       31    28   Feces             \[[@ref015]\]
  *Clostridium coccoides, Clostridium leptum, Bacteroides fragilis, Prevotella* (ns)                                                                        *Lactobacillus sp.*                                                Targeted qPCR for 19 species   45    32   Feces             \[[@ref016]\]
  *Lachnospiraceae, Faecalibacterium prausnitzii.*                                                                                   *Akkermansia muciniphila, Bifidobacterium sp., Lactobacillus sp.*                                   16S rRNA             212   136  Feces             \[[@ref017]\]
  none                                                                                                                                     *Lactobacillaceae, Barnesiellaceae, Enterococcaceae*                                          16S rRNA             29    29   Feces             \[[@ref018]\]
  *Corpobacillaceae, Lachnospiraceae (Blautia sp., Dorea sp., Roseburia sp., Coprococcus sp.)*                                                               *Bacteroides sp.*                                                           16S rRNA             38    34   Feces             \[[@ref019]\]
  *Coprobacillaceae, Lachnospiraceae (Dorea sp.), Faecalibacterium sp.*                                                                                *Oxalobacteraceae, Ralstonia*                                                     16S rRNA             38    34   Sigmoid mucosa    \[[@ref019]\]
  *Blautia sp., Faecalibacterium sp., Ruminococcus sp.*                                                                             *Escherichia sp., Streptococcus sp., Proteus sp., Enterococcus sp.*                                  16S rRNA             24    14   Feces             \[[@ref020]\]
  *Lachnospiraceae*                                                                                                                                 *Eubacteraceae, Bifidobacteraceae*                                                   16S rRNA             75    45   Feces             \[[@ref021]\]
  *Dorea sp., Bacteroides sp., Prevotella sp., Faecalibacterium sp.*                                                  *Lactobacillus sp., Christensenella sp., Catabacter sp., Oscillospira sp., Bifidobacterium sp.*                    16S rRNA             89    66   Feces             \[[@ref022]\]
  *Prevotellaceae, Clostridales incertae sedis IV*                                                             *Lactobacillaceae, Verrucomicrobiaceae (Akkermansia), Bradyrhizobiaceae, Ruminococcaceae, Enterobacteriaceae*             16S rRNA             72    72   Feces             \[[@ref012]\]
  *Lactobacillus, Sediminibacterium*                                                                            *Clostridium IV, Aquabacterium, Holdemania, Sphingomonas, Clostridium XVIII, Butyricicoccus, Anaerotruncus*              16S rRNA             45    45   Feces             \[[@ref013]\]
  *Bacteroidetes, Lactobacilli, Faecalibacterium sp., Enterococcaceae, Prevotellaceae* (ns)                                                      *Enterobacteriaceae, Bifidobacterium sp.*                                       Targeted qPCR for 9 taxa     34    34   Feces             \[[@ref014]\]

Updated table adapted and merged from \[[@ref025]\] and \[[@ref026]\]; \*Also significant after the two-year follow up; ns, not significant.

###### 

Bacterial metabolites significantly altered in PD patients compared to healthy controls

  Study              Sample        PD     Healthy                 Method                                                                                                          Decreased (FC, PD vs HC)                                                                                                                                                                                    Increased (FC, PD vs HC)                                                                                                                                                                                                                                                            Description
  --------------- ------------- -------- --------- ------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \[[@ref029]\]        CSF         34       35                     GC-MS                                                                                                                    none                                                                                                                                                                                                        none                                                                                                                                                                                                                                                            Lumbar puncture after fasting.
  \[[@ref031]\]        CSF         31       95                   FT-ICR-MS                                                                                                                  none                                                                                                                                                                                    *p*-cresol sulfate (9.29); quinic acid (1.7)                                                                                                                                                                                                                Lumbar puncture; 18 patients without PD medications and 11 with PD medication.
  \[[@ref090]\]        CSF         48       57                   GC/LC-MS                                                                                                                   none                                                                                                                                                                                                        none                                                                                                                                                                                                                                          Postmortem (within 4 hours) collection of lateral ventricular CSF.
  \[[@ref091]\]        CSF         10       10                  1D ^1^H-NMR                                                                                                                 none                                                                                                                                                                                                        none                                                                                                                                                                                                                                      Six patients started dopaminergic treatment at the time of CSF collection.
  \[[@ref055]\]    CSF, Plasma     20       20                   GC-TOF-MS                                                                                                                  none                                                                                                                                                                                                        none                                                                                                                                                                                                                                    PD baseline; Samples were collected without overnight fasting, between 8-9 AM.
  \[[@ref048]\]    CSF, Plasma   49^\*^     NA                   LC-GC-MS                                                                           Correlation with the progression of PD: Benzoic acid (CSF: *r* = --0.42, plasma: ns)                                                                                                                          Correlation with the progression of PD: indoleacetic acid (CSF:0.29, plasma: ns)                                                                                                                                          ^\*^Placebo treated PD patients from study from 1989. Lumbar puncture for CSF samples and blood samples were collected after overnight bed rest (between 6 and 10 AM before breakfast).
  \[[@ref092]\]    CSF, Plasma     22       28                   GC/LC-MS                                                                                                   3-(4-hydroxyphenyl)acetic acid (NA)                                                                                                                                                                                      indole (NA)                                                                                                                                                                                                                Lumbar puncture and plasma samples from non-fasting patients; Samples were age, sex, and sampling-date matched.
  \[[@ref093]\]    CSF, Plasma     26       14                     LC-MS                                                                                                                    none                                                                                                                                                                                                        none                                                                                                                                                                                           Lumbar punctures were performed between 09.30 and 10.00 am after overnight fasting; Blood was drawn from the cubital fossa immediately after the lumbar puncture.
  \[[@ref037]\]      Plasma        43       37                  2D ^1^H-NMR                                                                                          trimethylamine (NA), acetate (NA), threonate (NA)                                                                                                                                                                                  none                                                                                                                                                                                                                            Samples were obtained from drug-naïve PD patients with age and gender-matched healthy controls.
  \[[@ref094]\]      Plasma        53       46                    LC-ECA                                                                                                                    none                                                                                                                                                                                                        none                                                                                                                                                                                          53 PD patients (41 iPD, 12 LRRK2^G2019S^) were compared to 31 healthy family members (21 positive and 10 negative for LRRK2 mutation) and 15 non-related controls.
  \[[@ref028]\]       Serum        35        7                   GC/LC-MS                                                                                                         indoleacetic acid (0.67)                                                                                                                                                                     phenyllactate (1.84); 3-(4-hydroxyphenyl)lactate (1.23)                                                                                                                                                                                                                           Blood was withdrawn after 4 hours of fasting.
  \[[@ref033]\]       Serum        41       40      DiscoveryHD4^TM^ Metabolon Platform                                                                                           catechol sulfate (0.62)                                                                                                                                                                                               none                                                                                                                                                                                                      Mass spectrometry-based; Blood was withdrawn after fasting from 41 idiopathic early-stage Parkinson's patients (disease duration \<1 year).
  \[[@ref030]\]       Serum        43       42                   CIT-LC-MS                                                                                                                  none                                                                                                                                                                                    vanillic acid (3.48) (mainly dietary source)                                                                                                                                                                              Determined of PD patients not developing dementia (*n* = 27) and PD patients that did develop dementia (*n* = 16). Blood was withdrawn at baseline.
  \[[@ref032]\]       Serum        28       18                     LC-MS                                                                                                                    none                                                                                                                                                                                                        none                                                                                                                                                                                                                                             Blood was withdrawn in the morning before any food or drink.
  \[[@ref024]\]       Serum        6        19                     LC-MS                  indoleacetic acid (0.82); hippuric acid (0.52); 3-hydroxyhippuric acid (0.39); catechol sulfate (0.62); 3-(3-hydroxyphenyl)propionic acid (0.49); indole-3-methyl acetate (0.70); 2-Furoylglycine (0.37)                                                                                                      none                                                                                                                                                                                                                                            PARK2 PD patients; Blood was withdrawn after overnight fasting.
  \[[@ref068]\]       Serum      48^\#^     10                     LC-MS                                                                                                    phenylethylamine (0.34^d^, 0.16^e^)                                                                                                                                                                              tyramine (1.70^d^, 2.44^e^)                                                                                                                                                                                               ^\#^21 *de novo* PD patients, ^d^*de novo* PD patients, ^e^treated PD patients; Blood was withdrawn in the morning after fasting.
  \[[@ref095]\]       Serum        80       20                 LC-FT-ICR-MS                                                                                                                 none                                                                                                                                                                                                        none                                                                                                                                                                       39 rapid progressing PD Patients and 41 slowly progressing PD patients. No fasting was required. No medication was allowed in the morning. Samples were taken at the morning exam between 8 AM and 12 PM
  \[[@ref035]\]       Urine       106       104                    LC-MS                                                                                                                    none                                                                                                                                        3-(4-hydroxyphenyl)acetic acid (1.96--2.16); tryptamine (2.22--3.31); indoleacetic acid (1.66--3.23); phenylacetic acid (2.36--2.71)                                                                                                                                                             After overnight fasting morning midstream urine samples were collected at week 0, 16 and 32.
  \[[@ref034]\]       Urine        92       65                   GC/LC-MS                                                                                                                   none                                                                                                     3-(4-hydroxyphenyl)acetic acid (1.66^a^, 2.78^b^, 5.85^c^); indoleacetic acid (2.64^a^, 3.49^b^, 1.88^c^); aminobenzoic acid (6.63^a^, 25.43^b^, 16.74^c^); hydroxybenzoic acid (4.30^a^, 4.26^b^, 6.68^c^)                                                                                After overnight fasting morning midstream urine samples were collected at week 0, 16 and 32; ^a^Early-stage (HY 1--1.5), ^b^Mid-stage (HY 2--2.5), ^c^Advanced-stage (HY 3-4).
  \[[@ref014]\]       Feces        34     44^\$^                   GC-MS                                                                           acetate (0.43^f^, 0.71^g^), butyrate (0.38^f^, 0.57^g^), propionate (0.48^f^, 0.61^g^)                                                                                                                                                               none                                                                                                       ^\$^34 age matched controls and 10 young healthy controls. Fold changes derived from figure compared to young controls^g^ and age matched controls^f^. All subjects were on an omnivorous diet without special dietary habits or restrictions. During the last 3 months no intake of antibiotics, probiotics, or prebiotics was reported.

^\*^Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364--1371. GC, gas chromatography; LC, liquid chromatography, MS, mass spectrometry; CIT, chemical isotope labeling; FT-ICR, Fourier-transform ion cyclotron resonance; NMR, nuclear magnetic resonance; LC-ECA, LC, electrochemical Array.

Comparing the 13 different studies in [Table 1](#jpd-9-jpd191780-t001){ref-type="table"}, 62% (8/13) report a decrease in species from the *Lachnospiraceae* family (including *Blautia sp.*, *Dorea sp.*, *Coprococcus sp.*, *Rosburia sp.*, and *Clostridium XIVa sp.*), 38% (5/13) report a decrease of *Faecalibacterium sp.,* and 15% (2/13) report a decrease in *Bacteroides sp*. (one study reported an increase), all of which are known to be SCFAs producers \[[@ref036]\].

In mouse models, it was shown that the gut microbiota is involved in *α*-synuclein aggregation pathology through their production of SCFAs \[[@ref023]\]. Using murine models overexpressing *α*-synuclein, germ-free (GF) or antibiotic treated mice had reduced PD pathology compared to conventional mice. In addition, when those GF or antibiotic treated mice were administered a mixture of SCFAs, the PD pathology was restored as observed in their conventional counterparts \[[@ref023]\]. GF mice (WT or overexpressing *α*-synuclein) colonized with human stool from PD patients had increased relative levels of butyrate and propionate but decreased levels of acetate compared to mice colonized with human stool from HCs \[[@ref023]\]. These findings are in contrast with the finding that PD patients have decreased levels of absolute SCFAs and reduced relative levels of butyrate but not acetate and propionate in their stool samples compared to age matched HCs \[[@ref014]\], which is in agreement with reduced levels of acetate found in the blood of PD patients \[[@ref037]\]. This discrepancy is most likely because of the differences between humans and mice, specifically those born germ-free. In addition, in Sampson et al. (2016) \[[@ref023]\] mice were recolonized with human faecal transplant, representing more acute effects as well as shifts in the microbiome based on species effects.

A decrease in *Prevotellaceae* or *Prevotella sp*. was observed in 31% (4/13) of the studies listed in [Table 1](#jpd-9-jpd191780-t001){ref-type="table"}. *Prevotella* produces (among others) hydrogen sulfide (H~2~S), a gasotransmitter (for review see \[[@ref038]\]), which has been linked to PD and neuroprotection \[[@ref039]\]. Free H~2~S levels in plasma, cecum, and colon of germ-free mice were significantly reduced compared to their conventional counterparts, indicating that the microbiota contributes to free H~2~S levels \[[@ref040]\]. H~2~S breathing (40 ppm) restored the movement disorder, protected dopaminergic neurons, prevented microglia and astrocyte activation and upregulated the expression of antioxidant genes from the Nrf2 pathway in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced PD mouse model \[[@ref041]\]. Similar results were found in a 6-hydroxydopamine (6-OHDA) and rotenone induced PD rat model receiving 30 or 100*μ*mol/kg NaHS (an H~2~S donor) \[[@ref042]\]. Similarly, H~2~ another and potentially overlooked gasotransmitter, which can be produced by gut microbiota, such as *Blautia sp. Clostridium spp.*, might have an important link to PD as it has been described to neutralize toxic hydroxyl radicals, downregulate the expression of proinflammatory factors, and preserve cerebrovascular reactivity \[[@ref043]\]. Intriguingly, 0.08 ppm of H~2~ in drinking water reduced the loss dopaminergic neurons by 16% compared to the control in the substantia nigra and slightly improved the mobility in an open-field test using a MPTP induced PD mouse model \[[@ref044]\]. Similarly, the protection of dopaminergic neurons, by drinking hydrogenated water, was also observed in a 6-OHDA rat model \[[@ref045]\]. Bacterial species representing the genera of bacteria altered in PD have been tested for their production of H~2~ \[[@ref046]\]. *Blautia coccoides* and *Clostridium leptum,* which are reported to be underrepresented in PD patients ([Table 1](#jpd-9-jpd191780-t001){ref-type="table"}) produced the highest levels of H~2~ (∼1.6 and 0.62*μ*mol/10^8^ cells) \[[@ref046]\], and therefore might contribute to the availability of molecular H~2~ which potentially plays a role in neuroprotection.

Other organic metabolites produced by *Clostridium* species \[[@ref047]\] were found to be differentially present in serum, urine, and CSF samples of PD patients ([Table 2](#jpd-9-jpd191780-t002){ref-type="table"}). For example, an increase in 3-phenyllactate, and 3-(4-hydroxyphenyl)lactic acid and a decrease of indoleacetic acid (IAA) was observed in serum of patients with idiopathic PD and familial PD (PARK2 mutations) \[[@ref024]\], although in urine, an increase of 3-(4-hydroxyphenyl)acetic acid and IAA was observed \[[@ref034]\]. In addition, a minor but significant correlation was observed between IAA and the progression of PD in CSF but not in plasma, however these samples were stored for 25 years before analysis on LC/GC-MS, which could influence the accuracy of sample analysis \[[@ref048]\]. IAA is produced via oxidative decarboxylation or deamination of indolepyruvate or tryptamine, respectively. Levels of IAA and tryptamine, produced by *Ruminococcus gnavus* and *Clostridium sporogenes*, are strongly dependent on the microbiota as GF mice showed ∼30 fold decrease in IAA cecal or fecal levels and a corresponding ∼10 fold decrease in tryptamine levels when compared to their conventional raised counterparts \[[@ref050]\]. Congruously to the increased IAA levels in urine, an increase in tryptamine was detected in urine of PD patients in one of the studies \[[@ref035]\]. Importantly, IAA was shown to modulate inflammatory responses reducing pro-inflammatory cytokine production by macrophages stimulated with LPS and palmitate or attenuating the cytokine mediated lipogenesis through the aryl hydrogen receptor (AHR) in hepatocytes \[[@ref051]\]. Furthermore, IAA has an anti-neuroinflammatory activity in LPS-stimulated BV2 microglial cells \[[@ref052]\]. Taken together, data available suggest that altered levels of IAA, which are caused by changes in microbial composition, might play a role in attenuating inflammation in PD patients.

*p*-Cresol sulfate (sulfonated by the liver), which is exclusively produced by gut bacteria \[[@ref053]\], mainly by species belonging to *Clostridiaceae* (*Clostridium clusters I, IV, IX, XI, XIII, XIVa, XVI*) and *Bacteroidaceae* families \[[@ref054]\] ([Table 1](#jpd-9-jpd191780-t001){ref-type="table"}), is also observed to be ∼10 fold increased in in the CSF of PD patients \[[@ref031]\] but not in blood samples \[[@ref024]\]. However, differential metabolite levels in blood do not necessarily reflect CSF levels \[[@ref055]\]. *p*-Cresol has a profound effect on the inflammatory response of macrophages and T-cells \[[@ref056]\]. In murine peritoneal exudate cells (the adherent fraction, mainly macrophages) and in a J774.1 macrophage cell line, pre-treatment with *p*-Cresol at non-cytotoxic levels was able to inhibit Il-12 production after stimulation with heat-killed *Lactobacillis casei* \[[@ref056]\]. The same effect was observed later in murine peritoneal exudate cells and RAW276.3 macrophage cell-line stimulated with LPS or LPS and IFN*γ* \[[@ref058]\]. In addition, *p*-Cresol sulfate increased Il-10 levels but did not alter levels of TNFa \[[@ref058]\]. In a hypersensitive mouse model, *p*-Cresol and *p*-Cresol sulfate correlated negatively with ear swelling, suggesting that *p*-Cresol (sulfate) attenuates T cell mediated immune response \[[@ref057]\]. When *in vitro* CD3^+^ splenocytes were stimulated with *p*-Cresol or *p*-Cresol sulfate a decrease in IFN*γ* and an increase IL-4 levels were observed, which was confirmed by a decreased Th1/Th2 ratio (CD3^+^/CD4^+^ splenocytes, intracellular stained for IFN*γ* (Th1) or IL-4 (Th2) production), but no difference between untreated and *p*-Cresol treated cytotoxic T-cells or regulatory T-cells were found \[[@ref057]\].

In contrast to *p*-Cresol sulfate, catechol sulfate, a product of bacterial and human co-metabolism, was found to be decreased in PD patients \[[@ref024]\]. Catechol is an intermediate bacterial product from the benzoate degradation pathway \[[@ref059]\]. Notably, higher bacterial metabolism of catechol seems to be associated with inflammation as concluded from the higher relative abundance of bacteria representing the benzoate pathway are higher in a murine colitis model during the active disease compared to remission \[[@ref060]\]. For example, *Ralstonia pickettii*, which is known to produce and degrade catechol \[[@ref061]\] was reported to be increased in the sigmoid mucosa of PD patients ([Table 1](#jpd-9-jpd191780-t001){ref-type="table"}) potentially reflecting inflammation \[[@ref019]\], which is in agreement with the reported higher abundance of bacteria representing the benzoate degradation pathway \[[@ref060]\].

Molecular mimicry by extracellular amyloid proteins produced by bacteria have been proposed as one potential trigger inducing misfolding of neuronal proteins via cross-seeding \[[@ref063]\]. Recently the amyloid protein produced by *Escherichia coli* (curli) has been implicated in *α*-synuclein pathology in rats and *Caenorhabditis elegans* \[[@ref064]\]. Rats orally administered with wild type *E. coli* or *E. coli* lacking the curli-gene revealed increased *α*-synuclein aggregates in the brain and gut of rats (hippocampus, striatum, and enteric nervous system) when treated with wild type *E. coli*. Furthermore, increased expression of IL-6, TLR2 and TNF were observed in the striatum or rats treated with wild type *E. coli* \[[@ref064]\]. Various species from the *Enterobacteriaceae* family (*E. coli*, *Salmonella typhimurium Citrobacter sp*., *Citrobacter freundii*, *Cronobacter sakazakii*, and *Proteus mirabilis*) produce curli \[[@ref065]\]. Importantly, 31% (4/13) of the studies reported increased abundance of *Enterobacteriaceae spp.* \[[@ref011]\] ([Table 1](#jpd-9-jpd191780-t001){ref-type="table"}). Intriguingly, oral administration of *P. mirabilis* in a MPTP induced PD mouse model induced neuronal damage, motor deficits, neuroinflammation and *α*-synuclein aggregation \[[@ref066]\]. The authors suggested that higher levels of LPS by *P. mirabilis* induced the observed neuronal damage. However, the fact that *P. mirabilis* produces curli could be another factor involved in the observed PD pathology.

BACTERIAL-MEDIATED SIDE EFFECTS OF PARKINSON'S DISEASE TREATMENT {#sec0015}
================================================================

Orally administered PD medication could have an effect on gastrointestinal (GI) function and therefore on the microbial composition alterations in PD patients. For example, the COMT-inhibitors, anticholinergics and levodopa/carbidiopa (borderline significant) were associated with microbiota alterations within PD patients \[[@ref017]\]. Furthermore, COMT-inhibitors were significantly associated with an increase of *Lactobacillaceae* and a decrease of *Clostridiales Family IV (Incertae Sedis)* \[[@ref012]\]. In 54% (7/13) of the studies *Lactobacillaceae* or *Lactobacillus* were reported to be increased in PD patients ([Table 1](#jpd-9-jpd191780-t001){ref-type="table"}). Some *Lactobacillus* species are known to produce tyramine \[[@ref067]\] and tyramine has been proposed as a biomarker for PD patients because of the significantly higher levels of tyramine compared to HC observed in the blood circulation (2.4 and 1.7 fold, respectively) \[[@ref068]\], [Table 2](#jpd-9-jpd191780-t002){ref-type="table"}. Although other studies did not find an increase in tyramine, an increase in the downstream metabolite of tyramine, 3-(4-hydroxyphenyl) acetic acid, was observed in PD patients \[[@ref034]\], potentially supporting increased levels of tyramine. The authors associated the human aromatic amino acid decarboxylase (AADC, also known as DOPA decarboxylase (DDC)) with the observed levels, without speculating about possible contribution of gut bacteria. Tyramine is abundant in fermented foods particularly produced by lactic acid bacteria (*Lactobacillus sp.*, *Enterococcus sp.*) harboring tyrosine decarboxylases (TDC), which are also commensals in the human GI-tract \[[@ref067]\]. Tyramine is produced in the small intestinal content of rat, indicating that small intestinal bacteria contribute to tyramine levels *in vivo*. In addition, *tdc*-gene abundance correlated positively (*r* = 0.82, *n* = 10) with the disease duration of PD \[[@ref071]\], supporting the increased abundance of *Lactobacillaceae* or *Lactobacillus* found in PD patients. Besides the decarboxylation of tyrosine to tyramine, the study also showed that bacteria harboring TDC can effectively decarboxylate levodopa to dopamine, and might compromise the levels of levodopa in the gut, before it can reach the brain \[[@ref071]\], which was later independently confirmed in human stool samples and using a TDC inhibitor in mice colonized with *E. faecalis* \[[@ref072]\]. Co-prescribed decarboxylase inhibiters, mainly carbidopa, prevent peripheral decarboxylation of levodopa treatment by the human AADC (DDC), which however do not affect the bacterial TDCs \[[@ref071]\]. The inadequate blocking of bacterial TDC might result in higher levels of luminal dopamine produced by the gut bacteria (65). Thus, because of levodopa treatment, PD patients are exposed to higher circulating levels of dopamine compared to matched HCs. Indeed, serum dopamine levels (sulfonated by the liver) are found to be 30--40 times higher compared to HC \[[@ref024]\] and serum dopamine levels correlated with the dosage of levodopa \[[@ref073]\]. Comparing healthy and PD subjects on either a low dose (400 mg/day) or a on a high dose (700 mg/day) of levodopa showed that PD patients on a high dosage of levodopa have significantly more dopamine in their peripheral blood lymphocytes (PBLs), however, (nor)epinephrine or DOPAC levels were not altered \[[@ref074]\]. In contrast, non-treated PD patients have low dopamine levels in their PBLs, even ∼3 fold lower than in healthy subjects, but after treatment showed an ∼30 fold increase in the PBL dopamine content \[[@ref075]\]. Likewise, higher levels of dopamine were detected in plasma of levodopa treated PD patients (∼2.5 fold increase) compared to HC or *de novo* PD patients and no significant differences were observed between HC and *de novo* PD patients \[[@ref076]\].

The high levels of dopamine exposure in PD patients, resulting from bacterial and human levodopa metabolism, could affect immune homeostasis, as dopaminergic systems are involved in either the adaptive and innate immune system, recently reviewed \[[@ref077]\]. Dopamine receptors are widely expressed on human leukocytes and dopamine, through its receptors, can modulate T-cell response, and might act as auto- or paracrine signaling molecule in the cells of the immune system \[[@ref078]\]. Importantly, the percentage of Dopamine Receptor D5 (DRD5) positive CD4^+^ T-cells correlated negatively with the UPDRS-III (Unified Parkinson's Disease Rating Scale, Part III, motor examination) score \[[@ref076]\], indicating that the severity (progression) of the disease, and thus the disease duration \[[@ref079]\] and drug treatment might be associated with reduced DRD5^+^ CD4^+^ T-cells. A follow up study investigating CD4^+^ T cell subsets (T helper cells, T~H1~, T~H2~, T~H17~; and T regulatory cells, T~reg~) showed an overall decrease of CD4^+^ T cells in *de novo* PD patients and treated PD patients attributed by a decrease in most T-cell subsets except for T~H1~. Remarkably, there were little differences observed between the *de novo* PD and treated PD patients except for T~reg~ mediated inhibition of T effector cell (T~eff~, mixture of T helper cells) proliferation by dopamine. T~reg~ subsets from healthy subjects, *de novo* PD patients, and treated PD patients showed similar T~reg~ mediated inhibition of T~eff~ proliferation, which is almost abolished by dopamine except for T~reg~ cells isolated from treated PD patients, those cells appeared to be insensitive to dopamine \[[@ref080]\]. This finding is consistent with an earlier report showing that dopamine prevents inhibition of murine T~eff~ proliferation by T~reg~ cells \[[@ref081]\]. Furthermore, it was shown that the effect of dopamine was mediated through DRD1-like receptors (DRD1 or DRD5) \[[@ref081]\], which is in agreement with the negative correlation observed between disease severity (and thus indirectly disease and treatment duration) and DRD5^+^ CD4^+^ T-cells in PD patients \[[@ref076]\]. This T~reg~ insensitivity might potentially be originated from the long-term levodopa treatment of PD patients. In addition, DRD2-like receptors (D2, D3, D4) seem to be involved in the dopaminergic immune pathway in PD. DRD3 knock out (KO) mice or RAG1 KO mice (which are devoid of T and B cells) reconstituted with DRD3-deficient splenocytes or DRD3-deficient CD4^+^ T cells resulted in a strong neuroprotection in MPTP-induced PD, showing a fundamental role of DRD3 expressed on CD4^+^ T cells in the degeneration of dopaminergic neurons. Furthermore it was shown that DRD3 deficient CD4^+^ T cells are unable to acquire the T~h1~ effector phenotype, indicating that dopaminergic signaling (by dopamine or agonists) through DRD3 would produce T~h1~ cells which are key in neurodegeneration observed \[[@ref082]\]. Which is in agreement with the higher Th1/Th2 ratio observed in progressing PD patients but not in *de novo* PD patients, potentially through dopamine mediated T~h1~ differentiation in combination with the inability of T~reg~ cells to inhibit T~eff~ cells \[[@ref080]\].

Besides levodopa, which results in higher exposer to peripheral dopamine, blocking DDC to avoid peripheral conversion of levodopa to dopamine, might have a profound influence on the immune system. Recently, it has been reported that carbidopa, a DDC inhibitor, has immunosuppressive properties as it prevents T-cell proliferation and T-cell autoimmunity in a mouse model \[[@ref083]\]. Furthermore, it has been demonstrated that carbidopa is an AHR-ligand \[[@ref084]\], and therefore might play a role in the immune system, as AHR is an important contributor to the adaptive immune system by modulating T-cell differentiation, reviewed recently \[[@ref085]\].

Importantly, proliferation of murine B-cell enriched lymphocyte cultures isolated from spleen, lymph nodes and Peyer's patches are inhibited by dopamine in a concentration dependent manner (1--100*μ*M), which coincided with immunoglobulin production (IgA, IgM, IgG) \[[@ref086]\]. IgA is known to shape the microbiota composition, reviewed here \[[@ref087]\], and thus a decrease in IgA production due to the exposure to dopamine could potentially lead to alteration in the microbiota composition. In a recent study, inflammatory markers in fecal samples of PD patients were compared to their HCs counterparts. The mean levels of the angiogenesis factor (Flt1), the pro-inflammatory cytokines IL-1*α*, and CXCL8 were significantly higher in PD patients. Importantly, consumption of probiotics was associated with significantly higher levels of the chemokines CCL4 (MIP-1*β*), and CCL17 (TARC), and the pro-inflammatory cytokine IL-7 \[[@ref088]\]. Unfortunately, the potential effect of anti-Parkinson medication on the fecal immune profiles was not included in the analysis, which could have a profound effect on the outcome (discussed above).

CONCLUSION {#sec0020}
==========

Microbial dysbiosis might be a contributing factor to the onset and/or progression and severity of PD. Altered bacterial composition might result in a change in bacterial metabolites as detected in PD patients, contributing to the immune homeostasis, and potentially detrimental for the onset and progression of the disease. Equally important is the pharmacological treatment of PD, which might further contribute to a disturbed immune system. Nonetheless, it remains to be elucidated what drives the modulation of the microbial composition in PD patients. Many studies have focused on the metabolic profile of PD patients in CSF, blood, or urine in order to find potential biomarkers for the etiology, onset, or progression of the disease. Many of these altered metabolites are bacterial products, reflecting a deviation in the microbial composition of PD patients, and therefore might act as an important biomarker for microbial dysbiosis. In addition, those bacterial-derived metabolites show important immunomodulatory properties, which might be important for the progression of the disease.

The main metabolites found have phenol/indole moieties and are mainly produced by bacteria from the Clostrida class, which are also known SCFAs producers. Notably, alterations in SCFAs were not reported in the majority of metabolomics studies, most likely because of the methods used for the untargeted metabolomics. Because SCFAs have a potential effect on the *α*-synuclein pathology, targeted metabolomics for SCFAs should be performed in future metabolomics studies, as they might give clues about abnormal levels in PD patients potentially influencing PD pathology. Furthermore, altered levels of SCFAs could be linked with the levels of p-cresol and IAA as these metabolites are produced mainly by Clostridia \[[@ref047]\], the main butyrate producing bacteria in the gut \[[@ref089]\]. Taken together, further research on the metabolites produced by the gut microbiota is necessary to unravel the complex interaction of multiple facets of metabolites originating from altered microbial composition and pharmacological treatment on the immune system in PD patients to give further insights on the role of gut microbiota and their metabolites on the onset, progression and etiology of the disease. Standardized methods of stool sampling and sequencing technology should be developed to generate more consensus among metabolomic and microbiota studies. Additionally studies should be conducted with focus on determining the fecal metabolome from PD patients in context of the pathology and progression of the disease. Diet as well as medication are confounding factors that influence changes in the microbiota, thus should be taken into consideration in the data analyses.
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